Novavax Inc. initiated testing of its coronavirus vaccine candidate in people and anticipates providing a first look in July
at what sort of immune responses are generated.
In the first part of the study, 130 healthy adult volunteers at two sites in Australia will get two doses of NVX-oV2373,
the biotech’s experimental vaccine. If the initial results look promising,
the company plans to quickly move into the second phase of the trial,
which would expand testing to other countries and age groups outside of 18 to 59.
Novavax’s valuation has swelled by more than 1,000% to about $2.7 billion since the start of the year
despite having no products on the market.
With about $388 million in funding from the Oslo-based Coalition for Epidemic Preparedness Innovations in its pocket,
Novavax has said it is targeting emergency-use authorization and production could be scaled up to 100 million doses by year end.
Novavax Starts Covid-19Study and Targets First Results in July,Vaccine to be tested on130healthy volunteers in Australia
at what sort of immune responses are generated.
In the first part of the study, 130 healthy adult volunteers at two sites in Australia will get two doses of NVX-oV2373,
the biotech’s experimental vaccine. If the initial results look promising,
the company plans to quickly move into the second phase of the trial,
which would expand testing to other countries and age groups outside of 18 to 59.
Novavax’s valuation has swelled by more than 1,000% to about $2.7 billion since the start of the year
despite having no products on the market.
With about $388 million in funding from the Oslo-based Coalition for Epidemic Preparedness Innovations in its pocket,
Novavax has said it is targeting emergency-use authorization and production could be scaled up to 100 million doses by year end.